Se connecter

Bibliographies thématiques / Post-Cancer / Articles de revues

Articles de revues sur le sujet « Post-Cancer »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Post-Cancer.

Auteur : Grafiati

Publié le 22 juin 2024

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Post-Cancer ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Mohamed Traore, Wend-Yam, Behyamet Onka, Ibrahima Dokal Diallo, Rachida Latib et Youssef Omor. « Post-radiotherapy recto-vaginal fistula in cervical cancer ». International Journal of Case Reports and Images 13, n^o 2 (3 octobre 2022) : 153–55. http://dx.doi.org/10.5348/101349z01wt2022ci.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Belyea, James, Robert Hart, Jonathan Trites et Mark Taylor. « Post Cancer Treatment ». Otolaryngology–Head and Neck Surgery 143, n^o 2_suppl (août 2010) : P152. http://dx.doi.org/10.1016/j.otohns.2010.06.246.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Madhu, Deepak, Syed Anjum Gardezi et Nadeem Tehami. « Is post-endoscopic ultrasound pancreatic cancer analogous to post-colonoscopy colorectal cancer ? » Endoscopy 55, n^o 01 (20 décembre 2022) : 102. http://dx.doi.org/10.1055/a-1881-4533.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Sharma, Abha. « Predictors of Post traumatic growth among breast cancer patients in Nepal ». Asian Pacific Journal of Health Sciences 4, n^o 2 (30 juin 2017) : 9–17. http://dx.doi.org/10.21276/apjhs.2017.4.2.3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Green, Nathan, Dale Treible et Harvey Wallace. « Prostate Cancer : Post-Irradiation Incontinence ». Journal of Urology 144, n^o 2 Part 1 (août 1990) : 307–9. http://dx.doi.org/10.1016/s0022-5347(17)39438-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Huang, Andy, George Tsavellas et Kirsten S. Hindle. « Colorectal cancer surveillance post-surgery ». Hospital Medicine 62, n^o 8 (août 2001) : 490–91. http://dx.doi.org/10.12968/hosp.2001.62.8.1626.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Maher, Ian, et Jeremy Bordeaux. « Post-Skin Cancer Alar Reconstruction ». Facial Plastic Surgery 29, n^o 05 (13 septembre 2013) : 351–64. http://dx.doi.org/10.1055/s-0033-1353375.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Audic, Yann, et Rebecca S. Hartley. « Post-transcriptional regulation in cancer ». Biology of the Cell 96, n^o 7 (septembre 2004) : 479–98. http://dx.doi.org/10.1016/j.biolcel.2004.05.002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Pradhan, S. A. « Post-cricoid cancer : An overview ». Seminars in Surgical Oncology 5, n^o 5 (1989) : 331–36. http://dx.doi.org/10.1002/ssu.2980050508.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Elshagie Habib Abdelmalak, E. « Prostate cancer surgery post infection ». European Urology Open Science 59 (janvier 2024) : S136. http://dx.doi.org/10.1016/s2666-1683(24)00123-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Meunier, M., M. Gaudé, A. Foncelle, L. Christophe, J. Berardet, S. Jacquin-Courtois et C. Confavreux. « Évaluation de la sarcopénie chez les patients en post-cancer : cohorte JUMP post-cancer ». Revue du Rhumatisme 90 (décembre 2023) : A285—A286. http://dx.doi.org/10.1016/j.rhum.2023.10.443.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

Sriwong, Kittipat, Kittisak Kerdprasop et Nittaya Kerdprasop. « Post-Operative Life Expectancy of Lung Cancer Patients Predicted by Bayesian Network Model ». International Journal of Machine Learning and Computing 8, n^o 3 (juin 2018) : 280–85. http://dx.doi.org/10.18178/ijmlc.2018.8.3.700.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Hope, Christopher Martin. « Immune profiling and cancer post transplantation ». World Journal of Nephrology 4, n^o 1 (2015) : 41. http://dx.doi.org/10.5527/wjn.v4.i1.41.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Smith, James. « AB008. Management of fertility post cancer ». Translational Andrology and Urology 5, S1 (avril 2016) : AB008. http://dx.doi.org/10.21037/tau.2016.s008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Devi, Mutum Sangeeta, et Asif Ahmed. « Oral manifestation of post cancer therapy ». Journal of Dental Specialities 9, n^o 2 (15 décembre 2021) : 53–56. http://dx.doi.org/10.18231/j.jds.2021.014.

Texte intégral

Résumé :

Oral cancer has become serious health issues. It is owing to a variety of factors including poor hygiene, tobacco usage, chewing tobacco, smoking, and others. Along with surgery and chemotherapy, the most common treatments include radiation therapy and chemotherapy. Patients with cancer may experience oral toxic effects as a result of antineoplastic therapy such as radiotherapy and chemotherapy. A variety of factors influence radiation, including the oral mucosa's fast cell turnover rate, the richness and complexity of the oral microbiota, and soft tissue stress during normal mouth function. The present literature review is for awareness regarding the main oral manifestation secondary to post cancer therapy.

Styles APA, Harvard, Vancouver, ISO, etc.

16

Semiglazov, V. F., M. A. Dzhelialova, S. S. Yerechshenko, E. T. Munaeva, R. S. Pesotsky, A. I. Tseluyko, A. S. Emelyanov, R. V. Donskikh et P. V. Krivorotko. « Post-neoadjuvant treatment of breast cancer ». Meditsinskiy sovet = Medical Council, n^o 9 (30 juillet 2020) : 232–41. http://dx.doi.org/10.21518/2079-701x-2020-9-232-241.

Texte intégral

Résumé :

Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual invasive disease following neoadjuvant chemotherapy, and the KATHERINE trial demonstrated a significant benefit of trastuzumabemtansine (TDM1) in patients with HER2-positive breast cancer who did not achieve a pathologic complete response, so we have a lot of interesting alternatives of post-neoadjuvant treatments for high-risk patients. The discovery of molecular markers of resistance to endocrinotherapy (cyclin-dependent kinases (CDK 4/6), ER mutation (ESR1), mTOR signaling pathway, co-expression of ER+/HER2+) and inhibitors to them expanded the possibilities of endocrinotherapy not only in advanced and metastatic breast cancer, but also in residual ER+ tumors. The pCR rates in hormone receptor-positive breast cancer after neoadjuvant chemotherapy are around 10%, which is much lower than the values observed in HER2-positive and triple negative subtypes, so new strategies are needed to improve pCR rates in this subgroup, even though the adjuvant endocrine therapy impacts significantly the outcomes of this patients. The cyclin-dependent kinases (CDKs) are serine–threonine kinases that regulate cell cycle progression from the G1 to the S-phase during mitosis. CDKs activity can be abnormally increased or dysregulated in breast cancer, leading to a constant stimulus for cell proliferation and survival, which is a known mechanism of resistance to endocrine treatment. The CDK inhibitors act on CDKs and block their activity, thereby restoring the cell cycle regulation. In studies with metastatic hormone receptor-positive breast cancer patients, the combination of a CDKis with first or second-line endocrine therapy showed significant improvements in progression-free survival and response rates. Evolving techniques such as next-generation sequencing and gene expression profiles have improved our understanding of the biology of residual disease and also the mechanisms involved in treatment resistance.

Styles APA, Harvard, Vancouver, ISO, etc.

17

RACHERIU, Mihaela, Sînziana Călina SILIȘTEANU et Maria Ramona COCA. « Post-therapeutic lymphedema in breast cancer ». Balneo Research Journal 10, Vol 10 No. 4 (10 décembre 2019) : 509–13. http://dx.doi.org/10.12680/balneo.2019.289.

Texte intégral

Résumé :

Introductions. Lymphedema is an interstitial accumulation of protein-rich lymph fluid, due to the post-therapeutic alteration of lymphatic circulation in the upper limb. The appearance of lymphedema is favoured by a number of risk factors. All of these factors ultimately lead to a process of tissue fibrosis. Materials and methods. This study was carried out in an outpatient regimen, for a period of 12 months, in the kinetotherapy room, using massage elements for lymphatic drainage and kinetotherapy technique. The study group included 15 patients aged 27-65 years.Results and discutions. Patients evaluated the quality of life after surgery based on the physical and mental symptoms, which is why anxiety, pain reduction through massage and kinetotherapy give patients self-confidence as well as confidence in the recovery process. Conclusions. This complex programme that includes lymphatic drainage massage methods and kinetotherapy techniques should be applied individually, progressively, under the control of the kinetotherapist. Key words: lymphedema, kinetotherapy technique, lymphatic drainage massage,

Styles APA, Harvard, Vancouver, ISO, etc.

18

Fu, Mei R., Sheila H. Ridner et Jane Armer. « Post-Breast Cancer Lymphedema : Part 1 ». AJN, American Journal of Nursing 109, n^o 7 (juillet 2009) : 48–54. http://dx.doi.org/10.1097/01.naj.0000357172.94131.58.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Fu, Mei R., Sheila H. Ridner et Jane Armer. « Post–Breast Cancer Lymphedema : Part 2 ». AJN, American Journal of Nursing 109, n^o 8 (août 2009) : 34–41. http://dx.doi.org/10.1097/01.naj.0000358492.91678.78.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Cordova, Matthew J., Michelle B. Riba et David Spiegel. « Post-traumatic stress disorder and cancer ». Lancet Psychiatry 4, n^o 4 (avril 2017) : 330–38. http://dx.doi.org/10.1016/s2215-0366(17)30014-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Wöll, Ewald. « Upper gastrointestinal cancer : POST ASCO 2013 ». memo - Magazine of European Medical Oncology 6, n^o 3 (septembre 2013) : 220–21. http://dx.doi.org/10.1007/s12254-013-0105-9.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Pall, Georg. « Post ASCO update 2016—lung cancer ». memo - Magazine of European Medical Oncology 9, n^o 4 (décembre 2016) : 215–18. http://dx.doi.org/10.1007/s12254-016-0302-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Fitzal, Florian. « Post San Antonio Breast Cancer Symposium ». memo - Magazine of European Medical Oncology 10, n^o 2 (30 mai 2017) : 50–51. http://dx.doi.org/10.1007/s12254-017-0334-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Wang, L. Y., et I. Ganly. « Post-treatment surveillance of thyroid cancer ». European Journal of Surgical Oncology 44, n^o 3 (mars 2018) : 357–66. http://dx.doi.org/10.1016/j.ejso.2017.07.004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Jewer, Michael, Scott D. Findlay et Lynne-Marie Postovit. « Post-transcriptional regulation in cancer progression ». Journal of Cell Communication and Signaling 6, n^o 4 (9 octobre 2012) : 233–48. http://dx.doi.org/10.1007/s12079-012-0179-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Francis, Anna, Eric Au, Wai H. Lim et Germaine Wong. « Post-transplant cancer : An epidemiological evaluation ». Journal of Onco-Nephrology 4, n^o 3 (14 septembre 2020) : 145–52. http://dx.doi.org/10.1177/2399369320953869.

Texte intégral

Résumé :

Kidney transplantation is a lifechanging event for patients with end-stage kidney disease (ESKD) because it improves the quality of life and survival of these patients. However, it is not a cure and is not without complications. Transplant recipients have an excess risk of premature death (largely from cancer and cardiovascular disease (CVD)) by at least 10-times compared to the general population. Published work has identified cancer as one of the most important and feared outcomes in transplant recipients and is a key research priority recognised by both patients and health professionals. There is also convincing epidemiological evidence, suggesting the overall risk of developing cancer in the transplant population is approximately 2 to 3-fold higher compared to the age-matched general population. Unlike CVD, where the death rates have fallen considerably over the past decade in this population in response to better screening, preventative and intervention approaches, the excess risk of cancer-related deaths in transplant recipients remains at least 10-fold higher compared to cancer patients in the general population. The causes of the increased risk of death are unknown but may be a consequence of possible differences in tumour biology under the influence of immunosuppression. In this review, we will discuss the epidemiology of overall and site-specific cancer risk and death across different countries. We will also focus on the current evidence on the prevention and screening in our at-risk transplant candidates. Finally, management strategies of common cancers such as skin, post-transplant lymphoproliferative disease and solid organ cancers such as colorectal, breast and lung cancer will be evaluated.

Styles APA, Harvard, Vancouver, ISO, etc.

27

Peters, M. « A26 Management of post-cancer fatigue ». European Journal of Oncology Nursing 14 (avril 2010) : S10—S11. http://dx.doi.org/10.1016/s1462-3889(10)70037-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Boonsiriphant, Piriya, Joel A. Hirsch, Alex M. Greenberg et Eric M. Genden. « Prosthodontic Considerations in Post-cancer Reconstructions ». Oral and Maxillofacial Surgery Clinics of North America 27, n^o 2 (mai 2015) : 255–63. http://dx.doi.org/10.1016/j.coms.2015.01.007.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Prisyazhiuk, Anatoly, O. A. Pjatak, V. A. Buzanov, GillianK Reeves et Valerie Beral. « Cancer in the Ukraine, post-Chernobyl ». Lancet 338, n^o 8778 (novembre 1991) : 1334–35. http://dx.doi.org/10.1016/0140-6736(91)92632-c.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

&NA;. « Immunosuppressants increase post-transplant cancer risk ? » Inpharma Weekly &NA;, n^o 1570 (janvier 2007) : 19. http://dx.doi.org/10.2165/00128413-200715700-00047.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Gofrit, Ofer, et Marina Orevi. « Post-operative surveillance in kidney cancer ». Annals of Translational Medicine 7, S3 (juillet 2019) : S136. http://dx.doi.org/10.21037/atm.2019.06.11.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Srivastava, Pranay, Bobby Jacob, Miral Subhani, Qi Tao et Kaleem Rizvon. « Post-Colonoscopy Rapidly Progressive Colorectal Cancer ». American Journal of Gastroenterology 113, Supplement (octobre 2018) : S907—S908. http://dx.doi.org/10.14309/00000434-201810001-01577.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Sonenberg, Nahum, et Nissim Hay. « Cancer Genomics : the post-transcriptional era ». Current Opinion in Genetics & ; Development 23, n^o 1 (février 2013) : 1–2. http://dx.doi.org/10.1016/j.gde.2013.02.016.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

Kayukova, E. V., et E. S. Bolotov. « POST-COVID SYNDROME IN CANCER PATIENTS ». Transbaikalian Medical Bulletin, n^o 1 (2023) : 149–55. http://dx.doi.org/10.52485/19986173_2023_1_149.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

d’Estaing, Sandrine Giscard, et Céline Chalas. « Gamete quality for post-cancer use ». Médecine de la Reproduction 26, n^o 1 (mars 2024) : 49–54. http://dx.doi.org/10.1684/mte.2024.0993.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Horst, H. A., K. Bäuning, A. Friedl, A. Müller, R. D. Kanitz et D. Weisner. « Improvement of cancer patients post-clinical care by cancer registries ». Journal of Cancer Research and Clinical Oncology 111, S1 (février 1986) : S62. http://dx.doi.org/10.1007/bf02580019.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Endo, Motoki, Go Muto, Yuya Imai, Kiyomi Mitsui, Katsuji Nishimura et Kazuhiko Hayashi. « Predictors of post-cancer diagnosis resignation among Japanese cancer survivors ». Journal of Cancer Survivorship 14, n^o 2 (13 novembre 2019) : 106–13. http://dx.doi.org/10.1007/s11764-019-00827-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Ross, Allyson, et Alison Mitchell. « Recovery in breast cancer - Areola micropigmentation post breast cancer surgery ». European Journal of Surgical Oncology 50 (mai 2024) : 108177. http://dx.doi.org/10.1016/j.ejso.2024.108177.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Lee, Jeeyeon, Jisang Yu, Samuel Schellenberg, Il-Young Chung, Ankit Bharat et Young Kwang Chae. « Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer. » Journal of Clinical Oncology 41, n^o 16_suppl (1 juin 2023) : e21061-e21061. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21061.

Texte intégral

Résumé :

e21061 Background: To evaluate the role of double lung transplantation (DLT) for lung cancer, the survival outcomes of patients who underwent DLT for lung cancer and the incidence of lung cancer after DLT were assessed. Methods: Data from case series reported in the literature were pooled and collected from the Organ Procurement Transplantation Network (OPTN) and the International Society of Heart and Lung Transplantation (ISHLT) registries. We evaluated the recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) of patients who underwent DLT for lung cancer. Moreover, the incidence and OS of post-transplant lung cancer in patients who received transplants for the non-cancerous disease were examined. Results: Regarding patients who underwent DLT for lung cancer, in the pooled (n = 19), OPTN (n = 15), and ISHLT (n = 25) data, 5-year RFS was 52.6%, 66.7%, and 80.0%, and 5-year OS was 57.9%, 26.7%, and 36.0%, respectively. The median CSS was 48.0 (range, 6.0–144.0), 27.7 (range, 0.2–66.6), and 24.0 (range, 0.1–145.1) months. Additionally, the application of cardiopulmonary bypass was associated with lower tumor recurrence in the pooled data (p = 0.004). The incidence and 5-year OS post-transplant lung cancer in patients who underwent DLT for the non-cancerous disease were 0.8% and 47.3% in the OPTN data and 0.6% and 50.7% in the ISHLT data, respectively. Conclusions: We demonstrated that reasonable survival outcomes can be achieved with DLT in patients with bilateral lung cancer. Further studies are required to evaluate the risk of post-transplant lung cancer in patients undergoing DLT for bilateral lung cancer.

Styles APA, Harvard, Vancouver, ISO, etc.

40

&NA;. « Immunosuppressants may increase cancer risk post-transplant ». Reactions Weekly &NA;, n^o 1134 (janvier 2007) : 1. http://dx.doi.org/10.2165/00128415-200711340-00001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Corrado, Ann Marie, et Monica L. Molinaro. « Post-traumatic growth following breast cancer treatment ». University of Western Ontario Medical Journal 86, n^o 1 (29 août 2017) : 14–15. http://dx.doi.org/10.5206/uwomj.v86i1.2138.

Texte intégral

Résumé :

Worldwide, breast cancer is the most commonly diagnosed cancer amongst women. Currently, in Canada, it is estimated that approximately 1 in 9 women will develop breast cancer at some point in their life, and 1 in 30 will die from it. With the growing proportion of women diagnosed with breast cancer each year, there is an expanding body of literature addressing the effect of undergoing breast cancer treatment. The survival rate has increased since the mid-1980s, and as such, more women are in remission from their treatment. To coincide with this, breast cancer literature has begun addressing the effects experienced by women after their treatment. The purpose of this article is to briefly review literature that suggests that women may experience post-traumatic growth after completing breast cancer treatment. Post-traumatic growth, or experiencing positive outcomes as a result of undergoing an extremely negative or traumatic experience, can include developing a new perspective on life, adopting routines to enhance one’s quality of life (such as diet and exercise habits), as well as increasing spirituality. This article will outline some potential outcomes of post-traumatic growth, as well as provide insight to health care providers on how to aid in transitioning women with breast cancer from treatment to life in remission.

Styles APA, Harvard, Vancouver, ISO, etc.

42

ALOUL, Adnan Al, Dan Florin UNGUREANU et Nicolae BACALBASA. « Post-resectional pelvic recurrences of rectal cancer ». Romanian Journal of Medical Practice 16, n^o 2 (30 juin 2021) : 202–6. http://dx.doi.org/10.37897/rjmp.2021.2.17.

Texte intégral

Résumé :

Introduction. Pelvic recurrence is not a rare event after resection with curative intent for rectal cancer originating from different segments of the rectum (lower, intermediary and superior part). Material and methods. This retrospective observational study included 106 patients; among these cases there were 79 patients who accepted surgical treatment of rectal cancer (treated in a governmental hospital between 2014 and 2017) and who were submitted to anterior resection with Hartmann’s procedure (6.5% of patients), anterior resection of rectosigmoid with colorectal anastomosis (78% of cases) and abdominoperineal resection (15% of cases). Results. After a 2 year follow-up, pelvic recurrence was reported in 11patients ~ 14% of cases: 33% rate of recurrence after Hartmann procedure, 9% rate of recurrence after abdominoperineal resection, and 10% rate of recurrence after anterior resection of rectosigmoid with colorectal anastomosis. 39 patients (49% of cases) had been submitted to preoperative radiotherapy: the pelvic recurrence rate among these cases was of 11% (9 patients). The rate of recurrence (RR) was also significantly influenced by the stage at diagnostic: stage III had RR = 52% of cases, stage II had RR = 41% of cases and stage I had RR = 0% of cases). The survival rate among surgically treated patients after 1 one year was 86%, and 80% in the first 2 years after treatment. Conclusions. Rectal cancer diagnosed in advanced stages has a high recurrence rate. A low recurrence rate indicates successful curative surgical treatment. The highest recurrence rate was reported after Hartmann procedure (which was usually performed as an emergency operation for locally advanced lesions).

Styles APA, Harvard, Vancouver, ISO, etc.

43

SIMONE, CARMINE. « PLATYPNEA-ORTHODEOXIA POST PNEUMONECTOMY FOR LUNG CANCER ». Chest 160, n^o 4 (octobre 2021) : A60. http://dx.doi.org/10.1016/j.chest.2021.07.092.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

Matuschek, Christiane, Danny Jazmati, Edwin Bölke, Bálint Tamaskovics, Stefanie Corradini, Wilfried Budach, David Krug et al. « Post-Neoadjuvant Treatment Strategies in Breast Cancer ». Cancers 14, n^o 5 (28 février 2022) : 1246. http://dx.doi.org/10.3390/cancers14051246.

Texte intégral

Résumé :

Neoadjuvant chemotherapy enables close monitoring of tumor response in patients with breast cancer. Being able to assess tumor response during treatment provides an opportunity to evaluate new therapeutic strategies. Thus, for triple-negative breast tumors, it was demonstrated that additional immunotherapy could improve prognosis compared with chemotherapy alone. Furthermore, adjuvant therapy can be escalated or de-escalated correspondingly. The CREATE-X trial randomly assigned HER2-negative patients with residual tumor after neoadjuvant therapy to either observation or capecitabine. In HER2-negative patients with positive BRCA testing, the OlympiA study randomly assigned patients to either observation or olaparib. HER2-positive patients without pathologic remission were randomly assigned to trastuzumab or trastuzumab–emtansine within the KATHERINE study. These studies were all able to show an improvement in oncologic outcome associated with the escalation of therapy in patients presenting with residual tumor after neoadjuvant treatment. On the other hand, this individualization of therapy may also offer the possibility to de-escalate treatment, and thereby reduce morbidity. Among WSG-ADAPT HER2+/HR-, HER2-positive patients achieved comparable results without chemotherapy after complete remission following neoadjuvant treatment. In summary, the concept of post-neoadjuvant therapy constitutes a great opportunity for individualized cancer treatment, potentially improving outcome. In this review, the most important trials of post-neoadjuvant therapy are compiled and discussed.

Styles APA, Harvard, Vancouver, ISO, etc.

45

&NA;. « Post-tamoxifen letrozole beneficial for breast cancer ». Inpharma Weekly &NA;, n^o 1512 (novembre 2005) : 11. http://dx.doi.org/10.2165/00128413-200515120-00029.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

46

SHIELD, P. W., B. DAUNTER et R. G. WRIGHT. « Post-irradiation cytology of cervical cancer patients ». Cytopathology 3, n^o 3 (juin 1992) : 167–82. http://dx.doi.org/10.1111/j.1365-2303.1992.tb00043.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

Brydoy, M., S. Fossa, O. Klepp, E. Wist, R. Bremnes et O. Dahl. « Post-treatment paternity in testicular cancer survivors ». Journal of Clinical Oncology 22, n^o 14_suppl (15 juillet 2004) : 4527. http://dx.doi.org/10.1200/jco.2004.22.14_suppl.4527.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Bartelink, H. « Breast cancer : Post-mastectomy radiotherapy : recommended standards ». Annals of Oncology 11 (2000) : 7–12. http://dx.doi.org/10.1093/annonc/11.suppl_3.7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Cooper, Sian, Toby Pillinger, Imtiaz Ahmed, Konrad Wolfe et Sidath H. Liyanage. « Perineal recurrence of prostate cancer post-brachytherapy ». BJR|case reports 5, n^o 3 (septembre 2019) : 20180104. http://dx.doi.org/10.1259/bjrcr.20180104.

Texte intégral

Résumé :

We present a rare case of perineal recurrence of prostate cancer post low dose rate brachytherapy. Increased levels of prostate-specific antigen were recorded 12 years post brachytherapy. Pelvic CT and MRI visualized a nodular lesion in the perineum, and positron emission tomography demonstrated choline-avidity. Ultrasound-guided biopsy of the nodule was performed, yielding histology consistent with prostatic adenocarcinoma. Metastatic prostatic seeding to the perineum is a rare complication of brachytherapy. We discuss the putative mechanism, approach to diagnosis, and management.

Styles APA, Harvard, Vancouver, ISO, etc.

50

Barbetakis, Nikolaos, Christos Asteriou, Athanassios Kleontas et Christos Lafaras. « Post-pericardiotomy syndrome following lung cancer surgery ». Interactive CardioVascular and Thoracic Surgery 11, n^o 6 (1 décembre 2010) : 871. http://dx.doi.org/10.1510/icvts.2010.248948a.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!